Metformin: An Insulin Sensitizer Used for Blood Sugar and Longevity Research

This article is for informational purposes only and does not constitute medical advice. Superpower Health facilitates access to metformin through licensed providers and compounding pharmacy partners. Always consult a qualified healthcare provider before starting any prescription medication.

A diabetes drug is now the most studied compound in aging research. The reason is not marketing. Metformin activates cellular pathways that overlap with caloric restriction, the most consistently replicated intervention shown to extend lifespan in animal models. Whether that translates to humans is the single most expensive question in longevity science right now.

Here is how metformin works at the cellular level, what the evidence supports beyond blood sugar control, and which biomarkers to track before and during use.

Key Takeaways

• Regulatory Status: FDA-approved since 1995 for management of type 2 diabetes
• Research Stage: Approved and marketed; generic widely available; longevity effects under active investigation
• Availability: Prescription only; available through Superpower's licensed provider network
• Prescribing information: View full prescribing information (DailyMed)
• How it works: Reduces hepatic glucose production and improves insulin sensitivity, primarily through AMPK pathway activation and mitochondrial complex I inhibition.
• What the research shows: In the UKPDS (N=753 overweight patients, median 10.7 years), metformin reduced HbA1c by approximately 1 to 1.5 percentage points versus diet alone; modest BMI reduction (MD −0.56 kg/m², 95% CI −0.74 to −0.37) versus placebo in non-diabetic adults with BMI ≥25 across 49 trials per Haber and colleagues' 2024 meta-analysis; longevity effects under investigation in the TAME trial.

What Is Metformin?

Metformin (brand names Glucophage, Fortamet, Glumetza) is a biguanide and the oldest widely prescribed oral diabetes medication in the world. It is used daily by approximately 150 million people worldwide. Its mechanisms extend considerably beyond blood sugar control, which is why researchers studying aging, cancer biology, and cardiovascular risk have converged on it as a candidate longevity intervention. Understanding how metformin works at the cellular level helps explain both its therapeutic profile and its side effects, and it makes clear why the longevity interest is scientifically grounded rather than speculative.

How Metformin Works in the Body

Hepatic Glucose Suppression

Metformin's primary action is in the liver. It suppresses hepatic glucose output by inhibiting gluconeogenesis, the process by which the liver converts non-sugar substrates such as amino acids and lactate into glucose. In practical terms, the liver releases less glucose into the bloodstream between meals and overnight. This is why fasting blood glucose typically drops first when someone starts metformin. The effect is dose-dependent and measurable within one to two weeks of initiation. A 2020 review in Endocrine Reviews by LaMoia and Shulman described both AMPK-dependent and AMPK-independent mechanisms for this hepatic action, with mitochondrial redox state changes playing a key upstream role.

AMPK Activation and Cellular Energy Sensing

Metformin inhibits mitochondrial complex I, which reduces ATP production and raises the cellular AMP-to-ATP ratio. This signals energy deficit to the cell and activates AMP-activated protein kinase (AMPK). AMPK is a master metabolic regulator: when active, it promotes glucose uptake in muscle, suppresses lipid synthesis, and inhibits mTOR (a key driver of cellular growth and anabolic signaling). This pathway overlaps with the cellular response to caloric restriction. A 2023 review in Nature Reviews Endocrinology by Foretz, Guigas, and Viollet provide a comprehensive updated account of these mechanisms and their downstream implications for aging biology and cancer risk. AMPK activation is the mechanistic bridge connecting metformin's glucose effects to its longevity research rationale.

Insulin Sensitization in Peripheral Tissues

Beyond the liver, metformin improves insulin sensitivity in skeletal muscle and adipose tissue. Insulin resistance in these tissues means that normal insulin concentrations produce suboptimal glucose uptake, requiring the pancreas to secrete more insulin to maintain blood sugar. Metformin reduces this requirement. Fasting insulin and HOMA-IR (homeostatic model assessment of insulin resistance) typically trend downward with metformin use, reflecting improved peripheral sensitivity rather than increased insulin secretion. This distinguishes metformin from sulfonylureas, which work by stimulating insulin release and carry hypoglycemia risk. Metformin does not cause hypoglycemia when used as monotherapy because it does not force insulin secretion.

Gut Microbiota Modulation

A growing body of evidence suggests metformin exerts meaningful effects through the gut. It alters the composition of the intestinal microbiome, increasing populations of bacteria such as Akkermansia muciniphila that are associated with improved metabolic function and gut barrier integrity. A 2019 RCT in the European Journal of Endocrinology by Ejtahed and colleagues demonstrated in a double-blind RCT (N=46; 1,000 mg/day metformin vs placebo, both with low-calorie diet, over 2 months) that metformin reduced BMI by 4.5% versus 2.6% with placebo in non-diabetic obese women, with associated gut microbiota alterations. This gut mechanism is likely a contributing factor to both the modest weight effects and the gastrointestinal side effects metformin is known for: the same microbiome disruption that may benefit metabolic health can cause nausea and loose stools in the early weeks of use.

What the Research Shows About Effectiveness

Type 2 Diabetes: The UKPDS

The UK Prospective Diabetes Study (UKPDS), published in The Lancet in 1998, followed 753 overweight participants randomized to metformin (titrated up to 2,550 mg/day) versus 411 on conventional diet alone for a median of 10.7 years. Participants randomized to metformin achieved a 32% reduction in diabetes-related endpoints (95% CI 13–47%, p=0.002) and a 36% reduction in all-cause mortality (95% CI 9–55%, p=0.011) compared to diet alone. This trial was among the first to demonstrate a mortality benefit for an oral diabetes medication and was instrumental in establishing metformin as the first-line pharmacological choice per ADA guidelines. The HbA1c reduction in UKPDS was approximately 0.6 percentage points versus diet alone (median 7.4% vs 8.0%), with larger reductions of 1 to 1.5 percentage points from baseline commonly observed in clinical practice at higher starting HbA1c levels.

Prediabetes Prevention: The DPP

The Diabetes Prevention Program (DPP), published in the New England Journal of Medicine in 2002, randomized 3,234 adults with prediabetes to placebo, lifestyle intervention, or metformin 850 mg twice daily. Participants in the metformin group showed a 31% reduction in progression to type 2 diabetes compared to placebo (incidence 7.8 vs 11.0 per 100 person-years) over a mean follow-up of 2.8 years. A 2023 landmark review in JAMA by Echouffo-Tcheugui and Perreault confirmed metformin's 31% diabetes risk reduction from DPP and noting the strongest benefit in individuals under 60 with BMI ≥35 or with a history of gestational diabetes. A 2018 study in the Journal of General Internal Medicine by Moin and colleagues systematically reviewed 40 studies (1998–2017) and documented that fewer than 1% of U.S. adults with prediabetes receive metformin, with the strongest evidence gap in those under 60, with BMI ≥35, or with a history of gestational diabetes.

Weight Reduction: Honest Expectations

Metformin is not a weight loss drug, and its weight effects are modest. A 2024 systematic review in Diabetes, Obesity and Metabolism by Haber and colleagues published a systematic review and meta-analysis of 49 trials (500–2,550 mg/day, minimum 3 months) confirming a mean BMI reduction of 0.56 kg/m² (95% CI 0.37–0.74, p<0.0001) versus placebo in non-diabetic adults with BMI ≥25. This is a meaningful but modest effect, substantially smaller than GLP-1 receptor agonists in PCOS-specific comparisons. A 2019 analysis in Annals of Internal Medicine by Apolzan and colleagues analyzed 1,066 DPP participants who lost ≥5% body weight in year one and found that over 15 years of follow-up, older age at randomization, greater first-year weight loss, and active metformin use predicted long-term weight maintenance, with the metformin group sustaining 6.2% weight loss versus 2.8% for placebo. Metformin is not FDA-approved for weight loss, and any weight-related benefit represents an off-label clinical judgment by the prescribing provider.

Longevity and the TAME Trial

The Targeting Aging with Metformin (TAME) trial, described by Barzilai and colleagues in Cell Metabolism, is the first clinical trial designed to test whether a drug can delay aging itself as a composite endpoint. The trial plans to randomize 3,000 subjects aged 65 to 79 to metformin (1,500 mg/day) or placebo over a planned 3.5-year follow-up, with a composite endpoint including incident cancer, cardiovascular disease, dementia, and mortality. As of 2025, the trial has not yet begun enrolling participants and is now being coordinated through ARPA-H (Advanced Research Projects Agency for Health) amid ongoing funding challenges. A 2020 study in Cell Metabolism by Kulkarni and colleagues provided the mechanistic rationale by reviewing evidence that metformin targets primary hallmarks of aging — including dysregulated nutrient sensing via AMPK activation, genomic instability, loss of proteostasis, and altered intercellular communication — through metabolic, antioxidant, and anti-inflammatory pathways across preclinical models. A 2021 review in Frontiers in Endocrinology by Mohammed and colleagues reviewed preclinical longevity data alongside clinical observational evidence, concluding that metformin holds genuine biological rationale as an aging intervention — citing observational data from the UK Clinical Practice Research Datalink showing that matched non-diabetic controls had 15% lower adjusted median survival time than metformin-treated diabetic patients (survival time ratio 0.85, 95% CI 0.81–0.90, per Bannister and colleagues' 2014 analysis of 78,241 metformin-treated subjects) — even before TAME results are available.

A Critical Counterpoint on Exercise

A 2019 RCT in Aging Cell by Konopka and colleagues published a notable finding: in a double-blind RCT (N=53, mean age 62, metformin 2,000 mg/day), metformin blunted exercise-induced mitochondrial adaptations in older adults. Over 12 weeks of aerobic exercise training, the metformin group showed no overall improvement in whole-body insulin sensitivity and abrogated gains in skeletal muscle mitochondrial respiration compared to placebo, with the increase in VO₂ max attenuated by approximately 50% (p=0.08). The proposed mechanism involves metformin's AMPK activation competing with or dampening the exercise-induced signaling cascade. This finding raises an important question for active individuals considering metformin for longevity purposes: the drug's anti-aging mechanism and exercise adaptation pathways may partially overlap, and the interaction in healthy active individuals is not yet resolved. Providers weighing metformin for off-label longevity use in physically active patients should discuss this tradeoff explicitly.

Side Effects and What to Expect

Most side effects with metformin are dose-dependent and improve with gradual dose titration or extended-release formulations. The most common issues occur early in treatment and often resolve within the first few weeks.

Common side effects:

• Nausea and gastrointestinal discomfort, particularly in the first one to two weeks (typically resolves with food co-administration and gradual dose titration)
• Loose stools or diarrhea, especially with immediate-release formulations (extended-release formulations reduce this substantially)
• Metallic taste (reported by a subset of patients; typically mild)
• Reduced appetite (contributes to the modest weight effects observed in clinical trials)

Less common but clinically important:

• Lactic acidosis (rare; risk increases significantly with renal impairment, which is why eGFR monitoring is required — contraindicated when eGFR falls below 30 mL/min/1.73 m²)
• Vitamin B12 depletion (dose-dependent and duration-dependent; a 2024 mini-systematic review in touchREVIEWS in Endocrinology by Atkinson and Gharti analyzed 21 studies and found that 17 of 21 reported a significant association between metformin use and lower B12 levels, with B12 deficiency risk increasing progressively with both dose and duration of use; the EMBER study published by Hurley and colleagues in 2023 found in 36,740 adults with type 2 diabetes that metformin users (n=6,221) had a 7.5% B12 deficiency rate versus 6.3% in non-users, with each additional year of use associated with 5% increased likelihood of deficiency and ≥4 years of use linked to 41% increased odds — providers recommend periodic B12 monitoring)
• Hypoglycemia when combined with insulin or insulin secretagogues (metformin alone does not cause hypoglycemia; the risk arises from combination therapy)

Providers monitor renal function and B12 levels during metformin therapy and adjust dosing or add supplementation based on individual response. The B12 depletion risk is the most clinically underappreciated effect of long-term metformin use and is the strongest argument for routine biomarker monitoring during therapy.

Who Is Metformin Typically Prescribed For?

Type 2 Diabetes

Metformin is the established first-line oral medication for type 2 diabetes per American Diabetes Association guidelines. Providers typically initiate it when HbA1c exceeds 6.5% and lifestyle modifications alone have not achieved target glycemic control. It is also used in combination with other diabetes medications as disease progresses. The UKPDS established its mortality benefit in this population over a median of 10.7 years, making it the first oral diabetes drug to demonstrate all-cause mortality reduction in a randomized outcomes trial.

Prediabetes and Insulin Resistance

Metformin is also prescribed for prediabetes and insulin resistance, which are not FDA-approved indications. The DPP trial demonstrated a 31% reduction in diabetes progression in high-risk individuals. Providers typically consider metformin in this context when HbA1c falls between 5.7% and 6.4%, fasting glucose is elevated, or fasting insulin and HOMA-IR indicate meaningful insulin resistance. Metformin is FDA-approved only for type 2 diabetes. No other uses have been approved by the FDA. The safety and efficacy for other uses have not been established through adequate and well-controlled clinical trials. Any off-label use is the independent clinical judgment of the prescribing physician.

PCOS

Polycystic ovary syndrome (PCOS) is frequently associated with insulin resistance, and metformin is widely used off-label in this population. A 2025 comprehensive review in Diabetes, Obesity and Metabolism by Saadati and Mason published a comprehensive review confirming metformin's utility in PCOS for addressing insulin resistance, metabolic disturbances, and ovulation induction. A 2023 update in JCEM by Melin and Forslund compared metformin to combined oral contraceptive pills in PCOS as part of the 2023 International PCOS Guidelines update. Again, PCOS is not an FDA-approved indication, and prescribing represents the independent clinical judgment of the provider.

Who Should Not Take Metformin

A licensed provider will evaluate individual risk factors before prescribing. The following are contraindications or conditions requiring additional clinical scrutiny:

• Severe renal impairment (eGFR below 30 mL/min/1.73 m²) — metformin is renally cleared; impaired clearance raises lactic acidosis risk; eGFR monitoring is required before and during therapy
• Active or decompensated liver disease — hepatic impairment reduces lactate clearance and increases lactic acidosis risk
• Planned contrast dye procedures — IV iodinated contrast can acutely reduce renal function; metformin is typically held before and after these procedures
• Acute or chronic metabolic acidosis, including diabetic ketoacidosis
• History of hypersensitivity to metformin
• Pregnancy (metformin use in pregnancy is an area of active research and clinical debate; management is individualized by a provider)

This is not an exhaustive list. A licensed provider will conduct a full clinical evaluation before determining eligibility.

What to Test Before Starting Metformin

Metformin's safety profile and therapeutic targets make pre-treatment testing clinically essential, not optional. The markers below address both the safety requirements of the drug and the baseline measurements needed to assess whether it is working.

• HbA1c: The primary outcome marker. Reflects average blood glucose over the preceding two to three months. Establishes whether metformin is indicated and provides the baseline against which treatment response is measured at three-month follow-up.
• Fasting glucose: Provides a point-in-time measure of blood sugar that responds within one to two weeks of starting therapy, making it the earliest indicator of metformin's hepatic glucose-suppressing effect.
• Fasting insulin: Together with fasting glucose, calculates HOMA-IR (insulin resistance index). Elevated fasting insulin reflects pancreatic compensation for peripheral insulin resistance and is one of the earliest detectable signs of metabolic dysfunction.
• eGFR (estimated glomerular filtration rate): Required before initiating metformin. Contraindicated below 30 mL/min/1.73 m²; use with caution between 30 and 45. Renal function monitoring is also recommended annually or if clinical status changes.
• Comprehensive metabolic panel (CMP): Covers liver function (ALT, AST) and kidney function (creatinine, BUN). Active hepatic disease is a contraindication; baseline liver enzymes establish a reference point for monitoring. The CMP also provides electrolytes and other safety markers.
• Vitamin B12: Metformin's most underappreciated long-term effect is B12 depletion. Establishing baseline B12 before starting allows providers to monitor for decline over time and initiate supplementation proactively. This is especially relevant for individuals already at risk of B12 deficiency.
• Lipid panel: Metformin significantly reduced total cholesterol and LDL-c in a 2020 meta-analysis of 47 RCTs (N=5,731 nondiabetic adults) by Weng and colleagues, though triglyceride changes did not reach statistical significance overall (MD −0.85 mg/dL, 95% CI −0.36 to 2.06, p=0.169), and may have favorable effects on LDL particle size. Baseline lipids provide context for cardiovascular risk assessment and allow tracking of any metabolic improvements during therapy.
• CBC (complete blood count): B12 deficiency can manifest as macrocytic anemia. Baseline CBC, combined with baseline B12, establishes whether any hematologic changes during therapy are pre-existing or treatment-related.

What Your Bloodwork May Show While on Metformin

After starting metformin, providers typically monitor HbA1c (expected to decrease by approximately 1 to 1.5 percentage points over three months in diabetic patients), fasting glucose (trending downward within one to two weeks), and eGFR (baseline and annual renal function monitoring). Fasting insulin and HOMA-IR should trend downward as insulin sensitivity improves, often before HbA1c reflects the change. Vitamin B12 may decrease over time, particularly after the first year of use; the EMBER study documented progressive risk increase with duration. Comparing these values to pre-treatment baseline is what makes the data clinically useful. Without that baseline, directional changes are difficult to contextualize.

That principle, measure first and act on what the data shows, is central to Superpower's approach to preventive health. Every medication decision should start with knowing where your biomarkers stand and continue with tracking how they respond over time.

Frequently Asked Questions

Can you take metformin for anti-aging without diabetes?

Metformin is not FDA-approved for anti-aging use. The TAME trial has been designed specifically to generate the evidence needed to evaluate metformin as an aging intervention in non-diabetic adults, though as of 2025 it has not yet begun enrolling participants. Metformin is FDA-approved only for type 2 diabetes. Any off-label prescribing for longevity, prediabetes, or metabolic optimization is the independent clinical judgment of the prescribing physician, not an FDA-approved use.

Does metformin cause B12 deficiency?

Yes, with duration and dose dependence. Metformin impairs B12 absorption in the ileum by interfering with calcium-dependent B12 transport. Systematic review data confirm that B12 deficiency risk increases progressively with both dose and duration of use. Routine B12 monitoring is recommended for anyone on long-term metformin. Supplementation can prevent or correct deficiency and is often initiated proactively by providers.

What is the best time of day to take metformin?

Metformin is typically taken with meals to reduce gastrointestinal side effects. For twice-daily dosing, morning and evening meals are the standard schedule. Extended-release formulations are usually taken once daily with the evening meal. Your provider will specify the dosing schedule based on the formulation prescribed and your individual tolerance.

Does metformin cause weight loss?

Metformin is associated with modest weight reduction in clinical trials, a mean BMI reduction of 0.56 kg/m² versus placebo in non-diabetic adults with BMI ≥25 based on a 2024 meta-analysis of 49 trials. This is a real but modest effect, substantially smaller than GLP-1 receptor agonists in PCOS patients. Metformin is not FDA-approved for weight loss. The mechanism is likely a combination of appetite reduction and gut microbiota changes rather than a direct fat-loss pathway.

Can you drink alcohol on metformin?

Heavy alcohol consumption is a risk factor for lactic acidosis when combined with metformin because alcohol impairs lactate clearance. Moderate alcohol intake is generally considered low-risk, but providers typically advise patients to avoid heavy or binge drinking while on metformin. If you drink regularly, disclose this to your prescribing provider so they can assess individual risk.

Does metformin blunt the benefits of exercise?

This is an active area of research. A 2019 study in Aging Cell by Konopka and Miller found in a double-blind RCT (N=53, mean age 62, metformin 2,000 mg/day, 12 weeks) that metformin attenuated exercise-induced gains in VO₂ max by approximately 50% (p=0.08), eliminated the improvement in whole-body insulin sensitivity, and abrogated gains in skeletal muscle mitochondrial respiration in older adults following aerobic training. The proposed mechanism is interference between metformin's AMPK activation and the AMPK signaling pathway triggered by exercise. Whether this represents a meaningful net negative for all metformin users is not yet established, but it is a legitimate consideration for physically active individuals, particularly those taking metformin for longevity purposes rather than metabolic disease management.

What blood tests should I get before starting metformin?

The essential pre-treatment markers are HbA1c, fasting glucose, fasting insulin, eGFR, a comprehensive metabolic panel, and vitamin B12. HbA1c and fasting glucose establish the metabolic baseline. eGFR and the CMP confirm safety eligibility. B12 establishes a baseline before the depletion effect begins. A CBC adds context for hematologic monitoring. See the blood sugar and insulin sensitivity biomarker guide for additional context on these markers.

This article is for informational purposes only and does not constitute medical advice. Superpower Health facilitates access to metformin through licensed providers and compounding pharmacy partners. Always consult a qualified healthcare provider before starting any prescription medication.